Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise in blood cancers but faces challenges in solid tumors due to poor T-cell infiltration and function.
• Limitations include CAR T-cell recruitment, infiltration, activation, and persistence within the tumor microenvironment.

Purpose of the Study:

• To review the rationale and ongoing clinical trials for combining CAR T-cell therapy with other treatment modalities for solid tumors.
• To explore how chemotherapy, radiation therapy, and immune checkpoint inhibitors can overcome CAR T-cell limitations.

Main Methods:

• Review of scientific literature and ongoing Phase I and II clinical trials investigating combination therapies.
• Analysis of the mechanisms by which chemotherapy, radiation, and immunotherapy enhance CAR T-cell activity.

Main Results:

• Chemotherapy can reduce immunosuppressive cells and create a pro-inflammatory environment, aiding CAR T-cell infiltration.
• Radiation therapy may improve CAR T-cell infiltration and activation by increasing chemokines and tumor antigen expression.
• Immune checkpoint inhibitors, like anti-PD1/PDL1, can enhance CAR T-cell persistence and endogenous anti-tumor immunity.

Conclusions:

• Combination strategies are essential for improving CAR T-cell efficacy in solid tumors.
• Ongoing clinical trials are evaluating various combinations, with safety, efficacy, and biomarker identification as key goals.
• Future research will focus on optimizing these combination regimens for better patient outcomes.